Reference : Nonmyeloablative stem cell transplantation with CD8-depleted or CD34-selected periphe...
Scientific journals : Article
Human health sciences : Hematology
http://hdl.handle.net/2268/9453
Nonmyeloablative stem cell transplantation with CD8-depleted or CD34-selected peripheral blood stem cells.
English
Baron, Frédéric mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
Baudoux, Etienne mailto [Centre Hospitalier Universitaire de Liège - CHU > > Thérapie cellulaire >]
Frere, Pascale mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
Tourqui, Soraya mailto [> > > >]
Schaaf-Lafontaine, Nicole mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie biologique et immuno hématologie >]
Greimers, Roland [Centre Hospitalier Universitaire de Liège - CHU > > Anatomie pathologique >]
Herens, Christian mailto [Centre Hospitalier Universitaire de Liège - CHU > > Génétique >]
Fillet, Georges mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
Beguin, Yves mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
2002
Journal of Hematotherapy & Stem Cell Research
Mary Ann Liebert, Inc.
11
2
301-14
Yes (verified by ORBi)
International
1525-8165
Larchmont
NY
[en] Adolescent ; Adult ; Aged ; Antigens, CD34/analysis ; Antigens, CD8/analysis ; Feasibility Studies ; Female ; Graft vs Host Disease ; Hematologic Neoplasms/complications/mortality/therapy ; Hematopoietic Stem Cells/immunology ; Humans ; Immunosuppression/adverse effects/methods ; Lymphocyte Depletion ; Male ; Middle Aged ; Peripheral Blood Stem Cell Transplantation/adverse effects/methods ; Survival Analysis ; Transplantation Chimera ; Transplantation Conditioning/adverse effects/methods ; Treatment Outcome
[en] To decrease the incidence of graft-versus-host disease (GVHD) observed after nonmyeloablative stem cell transplantation (NMSCT), we studied the feasibility of CD8-depleted or CD34-selected NMSCT followed by CD8-depleted preemptive donor lymphocyte infusion (DLI) given in incremental doses on days 40 and 80. Fourteen patients with high-risk malignancies and an HLA-identical sibling (n = 8) or alternative donor (n = 6) but ineligible for a conventional transplant were included. Nonmyeloablative conditioning regimen consisted in 2 Gy total body irradiation (TBI) alone, 2 Gy TBI and fludarabine (previously untreated patients) or cyclophosphamide and fludarabine (patients who had previously received > or =12 Gy TBI). Patients 1-4 (controls) received unmanipulated peripheral blood stem cells (PBSC) and DLI and patients 5-14 CD8-depleted or CD34-selected PBSC followed by CD8-depleted DLI. Post-transplant immunosuppression was carried out with cyclosporine A (CsA) and mycophenolate mofetil (MMF). Initial engraftment was seen in all patients, but 1 patient (7%) later rejected her graft. The actuarial 180-day incidence of grades II-IV acute GVHD was 75% for patients 1-4 versus 0% for patients 5-14 (p = 0.0019). Five of 14 patients were in complete remission (CR) 180 days after the transplant and 6/14 had partial responses. The 1-year survival rate was 69%, and nonrelapse and relapse mortality rates were 16 and 18%, respectively. We conclude that CD8-depleted or CD34-selected NMSCT followed by CD8-depleted DLI is feasible and considerably decreases the incidence of acute GVHD while preserving engraftment and apparently also the graft-versus-leukemia (GVL) effect. Further studies are needed to confirm this encouraging preliminary report.
http://hdl.handle.net/2268/9453
10.1089/152581602753658484

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
155.pdfPublisher postprint304.72 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.